Estradiol/progesterone - TherapeuticsMD

Drug Profile

Estradiol/progesterone - TherapeuticsMD

Alternative Names: 17β-estradiol/progesterone -TherapeuticsMD; Progesterone/estradiol - TherapeuticsMD; TX 12-001-HR; TX-001HR; TX-006HR; TX-008HR

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator TherapeuticsMD
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Pregnenediones
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Endometrial hyperplasia; Menopausal syndrome

Most Recent Events

  • 05 Dec 2016 Top-line safety and efficacy results from the phase III Replenish trial in Menopausal syndrome released by TherapeuticsMD
  • 01 Nov 2016 TherapeuticsMD completes its phase III trial for Menopausal syndrome and Endometrial hyperplasia in USA (NCT01942668)
  • 31 Aug 2016 Estradiol/progesterone is still in phase III trials for Endometrial hyperplasia (Prevention) and Menopausal syndrome in USA (PO) (TherapeuticsMD pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top